Please login to the form below
Aptalis
This page shows the latest Aptalis news and features for those working in and with pharma, biotech and healthcare.
HIV prevention pill heads July CHMP recommendations
Other positive recommendations were given for Aptalis' Truberzi (eluxadoline) as a treatment for irritable bowel syndrome with diarrhoea, along with two biosimilar versions of Sanofi's clot-busting drug Lovenox (enoxaparin) -
Latest news
-
Actavis claims top UK generics spot with Auden Mckenzie buy
Other acquisitions in the last 12 months have included $25bn for Forest Laboratories, $2.9bn for Aptalis, a $1.6bn deal for Furiex Pharma and $675m for Durata.
-
Forest Labs agrees $1.46bn deal to buy Furiex
Forest chief executive Brent Saunders said the Furiex deal "is a natural extension of our GI business following our $2.9bn acquisition of Aptalis earlier this year," adding that eluxadoline would
-
Forest said to be interested in $3bn Aptalis acquisition
The private equity group bought Aptalis for $1.3bn in 2008 and was looking to sell it on for $3bn-$4bn. ... The Aptalis rumour also comes shortly after Forest itself was the subject of speculation about a possible takeover by AstraZeneca.
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Pharma deals during February 2014
The announcement came just after Forest completed its acquisition of Aptalis last month for $3bn and this month sold a number of products to Hospira's Australian subsidiary Mayne Pharma for
-
Pharma deals during January 2014
Almost right to the end of the month, the big headline deal was that of Forest with its planned takeover of Aptalis. ... Aptalis itself was only formed in 2011 following the acquisition of Eurand by the Montreal based Axcan Pharma.
-
Deal Watch table for January 2014
4, 295. Aptalis/ Forest. Company acquisition. Acquiring sales turnover of $688m. 2, 900.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Intellia Therapeutics appoints Dr Moncef Slaoui and Dr Frank Verwiel
He has held numerous leadership roles including president and CEO of Aptalis Pharma prior to its acquisition by Forest Laboratories.
-
Lupin names chief corporate development officer
Theresa Stevens has experience at Novartis and Aptalis. Lupin has appointed Theresa Stevens as chief corporate development officer for its global operations. ... Stevens joins the India-based pharma company from Aptalis Pharma, where she was chief
-
Marino Garcia joins Synergy Pharmaceuticals
Garcia joins the New York-based gastrointestinal specialist from Aptalis Pharma, which also focused on the gastrointestinal market, as well as cystic fibrosis. ... Prior to his time at Aptalis Garcia was VP of US commercial operations and new product
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
-
Account Director – UK Office
-
Excellent salary and benefits
- Senior Account Executive – Account Manager – Healthcare Advertis...
-
£32000 - £43000 Bonus Benfits
- FREELANCE Account Director – Healthcare Advertising – London – 3...
-
Competitive Daily Rates
- Account Director, Healthcare Communications
-
Salary TBC
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
Subscribe to our email news alerts
- Finch Therapeutics bags $53m for microbiome therapies
- MSD taps Austria’s Themis to bolster vaccine pipeline
- Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate
- GSK preps filings for BCMA-targeting multiple myeloma drug
- Behaviour change – is there something missing?
- NICE’s long-serving chief exec Sir Andrew Dillon to step down
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- Empowered patients: shaking the foundations of healthcare
- Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
- A uniquely English genomic medicine service
- The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
- Blended Intelligence
- Data is the most valued commodity of the modern world. For P&P it's all about the application....
Quick links
Infographics
